A RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TWO DIFFERENT SIROLIMUS (SRL) REGIMENS WITH TACROLIMUS (TAC) + MYCOPHENOLATE MOFETIL (MMF) IN DE NOVO RENAL ALLOGRAFT RECIPIENTS: PRELIMINARY 2-YEAR SAFETY RESULTS FROM THE ORION TRIAL: 444